Although some studies have suggested that tumor-cell PD-L1 expression may correlate with benefit as compared to immune-cell PD-L1, the majority of available data indicate no meaningful differences in PD-L1 expression across anatomical BTC subtypes [34]. Here, CD274 is linked to neoplasm.